Boehringer backs €20B R&D game plan with a $272M blueprint for new facility — 100 new hires
Boehringer Ingelheim is backing their biologics focus in R&D with a $272 million investment in a new facility that will add another 100 staffers to the payroll.
The biotech company is adding a new development center in Biberach, Germany, which they plan to staff with 500 employees, including the new hires. The private company is planning on a staggered opening in 2020, bringing in the 500 employees while looking to beef up its capacity on “biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity.”
Boehringer has been on the march recently, adding a CD47 program by in-licensing a late-preclinical drug that targets SIRP-alpha and prevents CD47 from binding to it. Its venture arm also was backed up at the beginning of this year with an extra €150 million, underscoring its interest in finding new companies operating in the biologics arenas it’s most interested in.
The R&D organization at Boehringer includes about 8,000 staffers now, and the company recently committed to get 15 more drugs through to an approval in the next 7 years, committing €20 billion for the task. Getting a couple of new drugs approved each year is a serious challenge.
Boehringer has also experienced setbacks it prefers not to discuss. Most notably, the company quietly slipped out of a partnership with South Korea’s Hanmi after the drug they were partnered on was linked to patient deaths — something they managed to omit in their original statement. That’s a luxury only private companies can enjoy.
This is the latest in a series of global investments, where Boehringer has been creating a network of operations in Shanghai, Fremont, CA and Vienna.
“The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Fridtjof Traulsen, a senior vice president at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.”
Aeriel view of Biberach, Germany Shutterstock